"Researchers at Sunnybrook and Princess Margaret hospitals are dedicating a great deal of time and money to developing non-invasive alternatives to the surgeon's scalpel. Those non-invasive solutions for men with prostate cancer could also achieve the Holy Trinity of outcomes: Cancer control; maintaining a man's potency, and virtually eliminating incontinence."
With the advent of prostate specific antigen (PSA) test, a blood test that can indicate prostate cancer, more men are being diagnosed with prostate cancer while it is still curable.
"I believe that focal treatment is the future for early-stage, low-risk cancer. Considering the treatments that are currently approved and available worldwide, men with localized prostate cancer may often feel they must choose between active surveillance and radical therapy (surgery or radiation). Patients who opt to monitor their cancer run the risk of having the disease spread, while those who choose radical therapy are at increased risk for incontinence and impotence. I see focal therapy as a cost-effective solution that can potentially provide an optimal balance between cancer control and co-morbidity issues."
- Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH)